Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors by virtual screening

被引:11
|
作者
Zhou, Yeheng [1 ,2 ]
Peng, Jiale [1 ]
Li, Penghua [1 ]
Du, Haibo [1 ]
Li, Yaping [1 ]
Li, Yingying [1 ]
Zhang, Li [1 ]
Sun, Wei [2 ]
Liu, Xingyong [1 ]
Zuo, Zhili [1 ,2 ]
机构
[1] Sichuan Univ Sci & Engn, Sch Chem Engn, Zigong, Peoples R China
[2] Chinese Acad Sci, State Key Lab Phytochem & Plant Resources West Ch, Kunming Inst Bot, Kunming, Yunnan, Peoples R China
关键词
IDO1; Molecular docking; HipHop pharmacophore; 3D-QSAR; PAINS; PHENYL BENZENESULFONYLHYDRAZIDES; THERAPEUTIC TARGET; CRYSTAL-STRUCTURES; DERIVATIVES; DOCKING; MECHANISM;
D O I
10.1016/j.compbiolchem.2018.11.024
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In this study, a combination of virtual screening methods were utilized to identify novel potential indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. A series of IDOL potential inhibitors were identified by a combination of following steps: Lipinski's Rule of Five, Veber rules filter, molecular docking, HipHop pharmacophores, 3D-Quantitative structure activity relationship (3D-QSAR) studies and Pan-assay Interference Compounds (PAINS) filter. Three known categories of IDO1 inhibitors were used to constructed pharmacophores and 3D-QSAR models. Four point pharmacophores (RI-IDA) of IDOL inhibitors were generated from the training set. The 3D-QSAR models were obtained using partial least squares (PLS) analyze based on the docking conformation alignment from the training set. The leave-one-out correlation (q(2)) and non-cross-validated correlation coefficient (r(pred)(2)) of the best CoMFA model were 0.601 and 0.546, and the ones from the best CoMSIA model were 0.506 and 0.541, respectively. Six hits from Specs database were identified and analyzed to confirm their binding modes and key interactions to the amino acid residues in the protein. This work may provide novel backbones for new generation of inhibitors of IDOL.
引用
收藏
页码:306 / 316
页数:11
相关论文
共 50 条
  • [41] Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase 1 (HDAC1) Dual Inhibitors Derived from the Natural Product Saprorthoquinone
    Lin, Yang
    Zhang, Heyanhao
    Niu, Tong
    Tang, Mei-Lin
    Chang, Jun
    MOLECULES, 2020, 25 (19):
  • [42] Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
    Roehrig, Ute F.
    Majjigapu, Somi Reddy
    Chambon, Marc
    Bron, Sylvian
    Pilotte, Luc
    Colau, Didier
    Van den Eynde, Benoit J.
    Turcatti, Gerardo
    Vogel, Pierre
    Zoete, Vincent
    Michielin, Olivier
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 84 : 284 - 301
  • [43] Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors
    Pu, Qinglin
    Zhang, Hongjun
    Guo, Liangqin
    Cheng, Mangeng
    Doty, Amy C.
    Ferguson, Heidi
    Fradera, Xavier
    Lesburg, Charles A.
    McGowan, Meredeth A.
    Miller, J. Richard
    Geda, Prasanthi
    Song, Xuelei
    Otte, Karin
    Sciammetta, Nunzio
    Solban, Nicolas
    Yu, Wensheng
    Sloman, David L.
    Zhou, Hua
    Lammens, Alfred
    Neumann, Lars
    Bennett, David Jonathan
    Pasternak, Alexander
    Han, Yongxin
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (08): : 1548 - 1554
  • [44] Potent and selective next generation inhibitors of indoleamine-2,3-dioxygenase (IDO1) for the treatment of cancer
    Powers, Jay P.
    Walters, Matthew J.
    Noubade, Rajkumar
    Young, Stephen W.
    Marshall, Lisa
    Melom, Jan
    Park, Adam
    Shah, Nick
    Bjork, Pia
    Fridman, Jordan S.
    Beck, Hilary P.
    Chian, David
    McKinnell, Jenny V.
    Osipov, Maksim
    Reilly, Maureen K.
    Shunatona, Hunter P.
    Walker, James R.
    Zibinsky, Mikhail
    Jaen, Juan C.
    CANCER RESEARCH, 2015, 75
  • [45] Identification of putative Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) dual inhibitors for triple-negative breast cancer therapy
    Paranthaman, Priyanga
    Veerappapillai, Shanthi
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2025,
  • [46] Role of indoleamine 2,3-dioxygenase 1 (IDO1) and kynurenine pathway in the regulation of the aging process
    Salminen, Antero
    AGEING RESEARCH REVIEWS, 2022, 75
  • [47] A theranostic probe of indoleamine 2,3-dioxygenase 1 (IDO1) for small molecule cancer immunotherapy
    Wu, Ying
    Zhang, Yanhui
    Chen, Xi
    Hu, Yulu
    Dong, Guoqiang
    Guo, Yuan
    Sheng, Chunquan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 213
  • [48] Design, synthesis and biological evaluation of novel aryl-acrylic derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors
    Hu, Hao
    Li, Ming
    Wu, Di
    Li, Zhiwei
    Miao, Ruifeng
    Liu, Yajing
    Gong, Ping
    BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (14) : 3135 - 3144
  • [49] Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
    Fujiwara, Yu
    Kato, Shumei
    Nesline, Mary K.
    Conroy, Jeffrey M.
    DePietro, Paul
    Pabla, Sarabjot
    Kurzrock, Razelle
    CANCER TREATMENT REVIEWS, 2022, 110
  • [50] Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors
    Dolusic, Eduard
    Larrieu, Pierre
    Blanc, Sebastien
    Sapunaric, Frederic
    Pouyez, Jenny
    Moineaux, Laurence
    Colette, Delphine
    Stroobant, Vincent
    Pilotte, Luc
    Colau, Didier
    Ferain, Thierry
    Fraser, Graeme
    Galleni, Moreno
    Frere, Jean-Marie
    Masereel, Bernard
    Van den Eynde, Benoit
    Wouters, Johan
    Frederick, Raphael
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2011, 46 (07) : 3058 - 3065